Taiwan Precision Medicine Initiative

 

 

The Taiwan Precision Medicine Initiative (TPMI) is a partnership between Academia Sinica and top medical centers in Taiwan to bring genetic information into clinical practice. By profiling 1 million participants with a set of genetic markers designed for Taiwan, we aim to optimize patient care by preventing dangerous drug side-effects, early cancer screening for those at high risk, and encouraging life-style changes for those at risk for other serious diseases.

Join us

Clinical Practice of Precision Medicine

The genetic profile of each participant includes markers that predict how one is affected by various medications and the serious diseases one is at high risk for. The participants and doctors can use this knowledge to manage their care.

Identification of Genetic Risk for Diseases in Taiwan

Studying the relationship of genetic profiles and clinical information of 1 million participants, we will identify genetic factors that increase one’s risk for common disease. Guidelines for managing patients at high risk for serious diseases will be developed with Taiwanese disease experts for implementation in the clinic.

TPM SNP Array

Taiwan Precision Medicine Single Nucleotide Polymorphism (SNP) Array is both a genetic profiling platform and a genetic testing platform, which is based on the Taiwanese reference genome data and Taiwan Biobank whole genome sequencing data. In addition to the SNPs that define the genetic background of the participants, thousands of genetic markers known to be associated with disease risk are also included in the TPM array.

Genotyping Labs

A central lab with TAF (Taiwan Accreditation Foundation) certification is established in the Institute of Biomedical Sciences (IBMS) at Academia Sinica to produce technically certified data. In addition, five partner hospitals have built state-of-the-art space for the instruments and provided the personnel to perform genotyping.

TPMI IS A JOINT EFFORT OF ACADEMIA SINICA AND PARTNER HOSPITALS

三軍總醫院
中山醫學大學附設醫院
天主教輔仁大學附設醫院
佛教慈濟醫療財團法人
花蓮慈濟醫院
長庚醫療體系
林口長庚紀念醫院
高雄長庚紀念醫院
基隆長庚紀念醫院
嘉義長庚紀念醫院
高雄醫學大學附設中和紀念醫院
高雄市立小港醫院
高雄市立大同醫院
高雄市立旗津醫院
臺大醫院
臺大醫院癌醫分院(有收案但尚未列出至官網上)
臺大雲林分院
新竹臺大分院新竹醫院
新竹臺大分院生醫醫院
國泰綜合醫院
汐止國泰綜合醫院
彰化基督教醫院
臺中榮民總醫院
臺中榮民總醫院嘉義分院
臺中榮民總醫院灣橋分院
臺北市立聯合醫院
臺北榮民總醫院
臺北醫學大學
臺北醫學大學附設醫院
萬芳醫院
雙和醫院
嘉義基督教醫院
亞東紀念醫院
和信治癌中心醫院
Previous
Next

Partner Hospitals

  • TSGH
  • Chung Shan Medical University Hospital
  • Fu Jen Catholic University Hospital
  • Far Eastern Memorial Hospital
  • Koo Foundation Sun Yat-Sen Cancer Center
  • Hualien Tzu Chi Hospital
  • Changhua Christian Hospital
  • Chia-Yi Christian Hospital
  • Taipei Veterans General Hospital

Chang Gung Memorial Hospital

  • CGMH
  • Keelung CGMH
  • Kaohsiung CGMH
  • Chiayi CGMH

Kaohsiung Medical University Hospital

  • KMUH
  • KMHK
  • KMTTH
  • KMCH

Cathay General Hospital

  • CGH
  • Sijhih CGH

NTUH

  • NTUH
  • NTUH Yunlin Branch
  • NTUH Hsin-Chu Branch
  • NTUH Hsin-Chu Biomedical Park Branch

Taichung Veterans General Hospital

  • Taichung VGH
  • Taichung VGH Chiayi Branch
  • Taichung VGH Wanqiao Branch

Taipei City Hospital

  • Taipei City Hospital Zhongxiao Branch
  • Taipei City Hospital Zhongxing Branch
  • Taipei City Hospital Yangming Branch
  • Taipei City Hospital Heping Renai Branch
  • Taipei City Hospital Heping Fuyou Branch

Taipei Medical University Health Care System

  • TMUH
  • TMWH
  • SHH

Screening for Cancer Risk

The TPMI consortium is identifying Taiwanese-specific cancer predictors by studying the genetic profiles and electronic health records of all the TPMI participants. Mutations associated with high cancer risk are screened and the results will be shared with the patients once the tests are validated.

TPM array for genetic screening of cancer risk follows the recommendations provided by the American College of Medical Genetics and Genomics, the National Comprehensive Cancer Network, and ClinVar database for disease-related genetic variants detection and interpretation.

Polygenetic Risk Score

When sufficient data for a disease or symptom are available, the data will be analyzed using state-of-the-art artificial intelligence approaches to generate polygenic risk score (PRS) for common diseases. Working with disease experts from the medical societies in Taiwan, management guidelines for each disease based on PRS will be established.

Drugs

A number of genetic markers have been found to affect drug response. These markers affect optimal dosing of medications and/or predict the risk of serious side-effects. Selecting and dosing medication based on a person’s genetic profile prevent adverse drug reactions and ensure that the most efficacious medication is prescribed for the patient. In the TPMI, drug usage and dosing guidelines follow the recommendations by the United States Food & Drug Administration, the Clinical Pharmacogenetics Implementation Consortium, and the Pharmacogenetics Knowledge Base.

Genetic profiling of a large cohort in Taiwan

Tailored Health Management for All

01
1 million people will be enrolled by the end of June 2023
To establish a database consists of comprehensive clinical data and genetic profiles of a large cohort, 1 million participants from 16 medical centers will be enrolled within 4 years.
02
Obtaining informed consent and collect blood samples
While each hospital will enroll patients according to its own protocol, the basic approach is to obtain informed consent from the patient as they receive care at TPMI's partner hospitals followed by either getting a fresh blood sample or using residual blood samples collected for other clinical tests.
03
DNA extraction and genotyping
DNA extraction is performed on standard automatic equipment at each hospital for uniformity and quality control. Genotyping is either done at the hospitals or at the Academia Sinica. Genotype calls are made centrally for batches of 3,000 samples each to minimize batch effects and maximize accuracy.
04
Implementation of precision medicine in the clinic
As part of the project, the genetic profiles of TPMI participants will be incorporated into their medical records and the results (including those generated by future studies) will be used in their health management.

TPMI Participants

TPMI enrolled 563,661 subjects as of Oct. 4, 2022

1
Taichung VGH
1
CSH
1
CGMH
1
TMU-HCS
1
KMUH
1
TSGH
0
NTUH
1
HTCH
1
TVGH
1
KFSYSCC
1
CCH
1
FEMH
1
FJCUH
1
TPECH
1
CYCH
1
CGH

Join TPMI

Genetic profiling of a large cohort in Taiwan
Join Taiwan Biobank before *

Join TPMI at NTUH, CGMH, CGH, KMUH and FEMH

NTUH
CGMH
CGH
KMUH
KMTTH
KMHK
KMCH
FEMH

No. 128, Sec. 2, Academia Rd., Nangang Dist., Taipei City 115, Taiwan 

Location and Map   | tpmi@ibms.sinica.edu.tw | Privacy and Security

© 2020 Taiwan Precision Medicine Initiative |  designed by Resource Center for Translational Medicine